Britannia Life Sciences Inc. (BLAB.CN)
ValueMarkers Composite Index
DCF data not available
Britannia Life Sciences Inc. (BLAB.CN) — VMCI valuation read
BLAB.CN prints VMCI 40/100 inside the Healthcare sector, where the median sits at 50. The 10-point below-median delta is the cleanest single-number summary of Britannia Life Sciences Inc.'s composite stance, and in the mid-cap bucket it places the share behind the typical peer on the five-pillar mix.
On BLAB.CN, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.
**Investor frame.** BLAB.CN trades at 14.0x earnings, 22% below the Healthcare median of 18.0x; that is the value line. ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of -2.2x leaves covenant headroom; that is the risk line for Britannia Life Sciences Inc. on the trailing financials.
BLAB.CN fell 3.3% over the trailing 7 days, with a +5.2% read on a 30-day basis.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.